
New tools:

- ☐ Virtual courses
- ☐ HEARTS App
- **ENLACE**
- ☐ ESTIMA tool

Yenny A. Rodriguez, MD, MSc **HEARTS** in the Americas Pan American Health Organization (PAHO/WHO)















Why HEARTS in the Americas has been developing virtual courses?



Disparity among PHC professionals in the Region to access updated educational information on hypertension, CVD, and risk factors.



Rapid turnover of health personnel in PHC centers.



PHC physicians are responsible for assessing and providing accurate treatment approaches to patients with hypertension and CVD risk factors.



NPHCW play an important role in diagnosing hypertension and catching potential patients to receive adequate pharmacological treatment.









HEARTS Virtual Courses




















HEARTS Virtual Courses











HEARTS Virtual Courses













Select country and calculate

How to get an accurate blood pressure reading

Estimate cardiovascular risk

> Clinical pathway - Therapeutic recommendations

Other calculations

Glomerular Filtration Estimation

Body Mass Index

Instructions for using the calculator

HEARTS in the Americas



This work was carried out with the financial contribution of the Centers for Disease Control and Prevention in Atlanta, GA. U.S. HHS / CDC Award # 6 NU2HGH000081-01-01

Clinical pathway - Therapeutic recommendations



Trinidad and Tobago

Hypertension Clinical



ACCURATE BLOOD PRESSURE MEASUREMENT

MEASURE BLOOD PRESSURE IN ALL ADULTS AND AT ALL VISITS







CARDIOVAS

KNOW YOUR RISH DISEASE AND HO

CARDIOVASCULAR RISK CALCULATOR

Use the **HEARTS** App to assess your cardiovascular risk



Scan code to acce the cardiovascular



automatic devices

TREATMENT PROTOCOL

START TREATMENT IMMEDIATELY AFTER CONFIRMING HYPERTENSION

Blood Pressure ≥140/90 mm Systolic Blood Pressure ≥130 (Established cardiovascular disease, I

Cardiovascular risk		All Hypertensives	H
			WITH establishe cardiovascular dise
Blood Pressure TARGET <140/90 mmHg		1	
Systolic Blood Pressure TARGET <130 mmHg			1
ASPIRIN 81 mg/daily			1
High-dose statins:	ROSUVASTATIN 40 mg/daily		/
Moderate-dose statins:	ROSUVASTATIN 20 mg/daily		




consumption

ACE- Lisinophril 10mg plus (+) CCB - Amlodipine 5mg



Patient above target after repeat measurement ACE - Lisinopril 20mg plus(+)



- The HEARTS app is not intended to replace clinical judgment.
- It aims to help health professionals and individuals to improve their understanding of CVD risk and the importance of addressing modifiable risk factors and to support proven interventions.
- The optimization of this tool depends on using it properly and ensuring consistent implementation of the given recommendations.
- The HEARTS app is an important tool that can help improve the efficiency of interventions and the quality of care in PHC.







PAHO data portal on noncommunicable diseases, mental health, injuries and risk factors that bring data on a comprehensive set of indicators.



Users can explore data and share insights to support the efforts to reduce NCDs and improve the well-being of people in the Region of the Americas.



The data disseminated is provided by the PAHO Member States or obtained from official national sources.



Measures of morbidity and mortality are estimated by the WHO or PAHO technical units.










Burden of Diabetes mellitus: level by country

Rates per 100,000 population







HTN:CVD EstimaTool

Use the selectors below to set specific scenarios

1.- Location or population group Location name

LATIN AMERICA AND THE CARIBBEAN

Total population 656,098,097

from baseline:

2.- Programmatic intervention

Scale up population hypertension control (%)

from baseline: to target: 28.7 50.4 by scaling up: Diagnosis (Awareness) among people with hypertension (%) from baseline: to target: 63.2 80.0 Treatment among those aware of the condition (%) from baseline: to target: 90.0 85.0

Hypertension control among those treated (%)

53.4 70.0 Hypertension treatment cascade indicator targets

to target




3.- Number of years to reach the target?

5


<> 0


Expected ischemic heart disease (IHD) and stroke deaths averted by scaling up the population hypertension (HTN) control based on data from 36 countries of the Region of the Americas, 1990-2019






Summary of results





HTN:CVD EstimaTool Expected ischemic heart disease (IHD) and stroke deaths averted by scaling up the population hypertension (HTN) control based on data from 36 countries of the Region of the Americas, 1990-2019 Use the selectors below to set specific scenarios 1.- Location or population group Ischemic heart disease Stroke Location name Trinidad and Tobago 79.1 1,207 29.7 454 Total population deaths per 100K pop absolute deaths deaths per 100K pop absolute deaths 1.525.663 could be averted could be averted could be averted could be averted 2.- Programmatic intervention Predictive model for ischemic heart disease mortality Predictive model for stroke mortality Scale up population hypertension control (%) Expected mortality rate for the level of population HTN control Expected mortality rate for the level of population HTN control from baseline: to target: 100 20.9 50.4 100,000 population Death rate per 100,000 population 80by scaling up: Diagnosis (Awareness) among people with 60_58.6 hypertension (%) 136.4 from baseline: to target: Death rate per 60.0 80.0 28.8 57.3 Treatment among those aware of the condition (%) 20from baseline: to target: Model 0 20.9 20.9 90.0 77.8 20 40 100 20 40 100 Hypertension control among those treated (%) Prevalence of population HTN control (%) Prevalence of population HTN control (%) from baseline: to target 70.0 44.8 Cumulative deaths averted from ischemic heart disease and stroke over years 1,661 Hypertension treatment cascade indicator targets Interaction: hover over the chart to update results 1,428 1500-100 90.0 1,154 80.0 prevalence (%) 70.0 Deaths 1,207 1000-831 1,042 50.4 845 450 610 500-332 454 387 309 Aware Control / HTN 220 Treated / treated Control aware 2 5 1 3 3.- Number of years to reach the target? Summary of results <> 0

HTN:CVD EstimaTool





Summary of results


25

Expected ischemic heart disease (IHD) and stroke deaths averted by scaling up the population hypertension (HTN) control based on data from 36 countries of the Region of the Americas, 1990-2019









https://www.paho.org/journal/en /special-issues/hearts-americas





Original research

Association between population hypertension control and ischemic heart disease and stroke mortality in 36 countries of the Americas, 1990-2019: an ecological study

Ramon Martinez¹, Patricia Soliz², Norm R. C. Campbell³, Daniel T. Lackland⁴, Paul K. Whelton⁵, Pedro Ordunez⁶

ed citation Martinez R, Soliz P, Campbell NRC, Lackland DT, Whelton PK, Ordunez P. Association between population hypertension control and ischemic heart disease and stroke mortality in 36 countries of the Americas, 1990-2019; an ecological study. Rev Panam Salud Publica. 2022;46:e143. https://doi.org/10.26633/RPSP.2022.143

Objective. To quantify the association between the prevalence of population hypertension control and ischemic heart disease (IHD) and stroke mortality in 36 countries of the Americas from 1990 to 2019.

Methods. This ecologic study uses the prevalence of hypertension, awareness, treatment, and control from the NCD-RisC and IHD and stroke mortality from the Global Burden of Disease Study 2019. Regression analysis was used to assess time trends and the association between population hypertension control and mortality. Results. Between 1990 and 2019, age-standardized death rates due to IHD and stroke declined annually by 2.2% (95% confidence intervals: -2.4 to -2.1) and 1.8% (-1.9 to -1.6), respectively. The annual reduction rate in IHD and stroke mortality deaccelerated to -1% (-1.2 to -0.8) during 2000-2019. From 1990 to 2019, the prevalence of hypertension controlled to a systolic/diastolic blood pressure ≤140/90 mmHg increased by 3.2% (3.1 to 3.2) annually. Population hypertension control showed an inverse association with IHD and stroke mortality, respectively, regionwide and in all but 3 out of 36 countries. Regionwide, for every 1% increase in population hypertension control, our data predicted a reduction of 2.9% (-2.94 to -2.85) in IHD deaths per 100 000 population, equivalent to an averted 25 639 deaths (2.5 deaths per 100 000 population) and 2.37% (-2.41 to -2.33) in stroke deaths per 100 000 population, equivalent to an averted 9 650 deaths (1 death per 100 000 population).

Conclusion. There is a strong ecological negative association between IHD and stroke mortality and population hypertension control. Countries with the best performance in hypertension control showed better progress in reducing CVD mortality. Prediction models have implications for hypertension management in most popular tions in the Region of the Americas and other parts of the world.

Hypertension; cardiovascular diseases; mortality; noncommunicable diseases; Americas

In 2019, ischemic heart disease (IHD) and stroke were the (DALYs), respectively, in the Region of the Americas (1,2). first- and the second-leading causes of death, and the first- However, although age-standardized death and DALY rates for and the fourth-leading causes of disability-adjusted life years cardiovascular disease (CVD) decreased substantially between

- Pan American Health Organization, Washington, D.C., United States of America. ORCID 0000-0003-661-1208 E Ramon Martinez, martined/pahoozg.
 Pan American Health Organization, Washington, D.C., United States of America. ORCID 0000-0001-5733-6283 ica ORCID 0000-0001-5788-225X

- 0000-0002-2225-383X


Rev Panam Salud Publica 46, 2022 | www.paho.org/journal | https://doi.org/10.26633/RPSP.2022.143











Thanks for your attention

rodriguyen@paho.org